文献速递急性肾损伤血液净化与透析水电解质与酸碱

简化局部枸橼酸抗凝方案用于CVVH、CVVHDF和SLED:聚焦预防肾脏替代治疗相关低磷血症并优化酸碱平衡

Simplified regional citrate anticoagulation protocol for CVVH, CVVHDF and SLED focused on the prevention of KRT-related hypophosphatemia while optimizing acid-base balance.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本研究评估简化局部枸橼酸抗凝方案在CVVH、CVVHDF和SLED-f中的有效性与安全性,旨在预防肾脏替代治疗相关低磷血症并优化酸碱平衡。纳入47例需肾脏替代治疗的急性肾损伤或终末期肾病患者,低磷血症(血磷<2.5 mg/dL)总体发生率为6.6%,血磷水平维持在正常范围,酸碱平衡保持稳定,无枸橼酸蓄积发生。

要点

  • 简化局部枸橼酸抗凝方案用于CVVH、CVVHDF和SLED-f,低磷血症总体发生率为6.6%。
  • 血磷水平维持在正常范围,不受基线值和肾脏替代治疗模式影响。
  • 酸碱平衡保持稳定,无枸橼酸蓄积发生。

核心结论

  • 采用新型简化局部枸橼酸抗凝方案的数据提示,该方案对CVVH、CVVHDF和SLED有效且安全,可预防肾脏替代治疗相关低磷血症并维持酸碱平衡,无枸橼酸蓄积。

研究设计与样本

  • 研究纳入47例需肾脏替代治疗的急性肾损伤或终末期肾病患者,包括11例CVVH、11例CVVHDF和25例SLED-f,平均APACHE II评分为25±7.0。
  • 肾脏替代治疗采用Prismax系统(Baxter)和聚丙烯腈AN69滤器(ST 150,1.5 m2,Baxter),联合18 mmol/L预稀释枸橼酸溶液(Regiocit 18/0,Baxter)与含磷酸盐溶液(HPO42- 1.0 mmol/L,HCO3- 22.0 mmol/L;Biphozyl,Baxter)。
  • 需要时以五水甘油磷酸钠(Glycophos™ 20 mmol/20 mL,Fresenius Kabi Norge AS,Halden,Norway)补充磷酸盐丢失,每次治疗期间安排血清枸橼酸测定。
  • 分析数据来自连续三个每日8小时SLED-f sessions,以及单次72小时CVVH或72小时CVVHDF sessions。
  • 采用重复测量方差分析(ANOVA)评估变量均值差异(即血清磷酸盐、枸橼酸),因部分患者接受磷酸盐补充,采用重复测量协方差分析(ANCOVA)将磷酸盐补充作为协变量建模。

主要发现

  • 因不可逆滤器凝血导致的中断可忽略不计。
  • 低磷血症(血磷水平<2.5 mg/dL)总体发生率为6.6%,血磷水平维持在正常范围,不受基线值和肾脏替代治疗模式影响。
  • 酸碱平衡保持稳定,无枸橼酸蓄积发生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypophosphatemia is a common electrolyte disorder in critically ill patients undergoing prolonged kidney replacement therapy (KRT). We evaluated the efficacy and safety of a simplified regional citrate anticoagulation (RCA) protocol for continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) and sustained low-efficiency dialysis filtration (SLED-f). We aimed at preventing KRT-related hypophosphatemia while optimizing acid-base equilibrium. METHODS: KRT was performed by the Prismax system (Baxter) and polyacrylonitrile AN69 filters (ST 150, 1.5 m2, Baxter), combining a 18 mmol/L pre-dilution citrate solution (Regiocit 18/0, Baxter) with a phosphate-containing solution (HPO42- 1.0 mmol/L, HCO3- 22.0 mmol/L; Biphozyl, Baxter). When needed, phosphate loss was replaced with sodium glycerophosphate pentahydrate (Glycophos™ 20 mmol/20 mL, Fresenius Kabi Norge AS, Halden, Norway). Serum citrate measurements were scheduled during each treatment. We analyzed data from three consecutive daily 8-h SLED-f sessions, as well as single 72-h CVVH or 72-h CVVHDF sessions. We used analysis of variance (ANOVA) for repeated measures to evaluate differences in variables means (i.e. serum phosphate, citrate). Because some patients received phosphate supplementation, we performed analysis of covariance (ANCOVA) for repeated measures modelling phosphate supplementation as a covariate. RESULTS: Forty-seven patients with acute kidney injury (AKI) or end stage kidney disease (ESKD) requiring KRT were included [11 CVVH, 11 CVVHDF and 25 SLED-f sessions; mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score 25 ± 7.0]. Interruptions for irreversible filter clotting were negligible. The overall incidence of hypophosphatemia (s-P levels <2.5 mg/dL) was 6.6%, and s-P levels were kept in the normality range irrespective of baseline values and the KRT modality. The acid-base balance was preserved, with no episode of citrate accumulation. CONCLUSIONS: Our data obtained with a new simplified RCA protocol suggest that it is effective and safe for CVVH, CVVHDF and SLED, allowing to prevent KRT-related hypophosphatemia and maintain the acid-base balance without citrate accumulation. TRIAL REGISTRATION: NCT03976440 (registered 6 June 2019).

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Di Mario F, Sabatino A, Regolisti G, et al. Simplified regional citrate anticoagulation protocol for CVVH, CVVHDF and SLED focused on the prevention of KRT-related hypophosphatemia while optimizing acid-base balance. Nephrol Dial Transplant. 2023. PMID: 37037771. doi:10.1093/ndt/gfad068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。